Lectin, galactoside-binding, soluble, 1 mRNA (LGALS1 mRNA) (LGALS1 mRNA)

Galectin-1 mRNA (LGALS1 mRNA) is the transcript responsible for the synthesis of Galectin-1, a beta-galactoside-binding lectin that serves as a critical regulator of immune homeostasis and tumor progression (UniProt: P09382). In the context of oncology, this mRNA is frequently overexpressed, leading to high levels of Galectin-1 protein which facilitates immune evasion by inducing apoptosis in activated T cells and promoting the recruitment of regulatory T cells (PubMed: 15155834). Beyond its role in immunosuppression, the translation of this mRNA supports tumor angiogenesis and enhances the migratory and invasive capabilities of cancer cells (PubMed: 29109410). Therapeutic strategies targeting Galectin-1 mRNA, such as siRNA or antisense oligonucleotides, aim to silence the expression of the protein at the pre-translational level to overcome the limitations of protein-level inhibition (PubMed: 24441040). Preclinical studies have demonstrated that knockdown of LGALS1 mRNA can sensitize tumors to chemotherapy and radiation while restoring anti-tumor immune responses (PubMed: 21832145). Although most clinical-stage galectin inhibitors currently target the protein directly, mRNA-targeted approaches represent a promising avenue for achieving potent and specific modulation of the Galectin-1 pathway in diseases like glioblastoma and pancreatic cancer.

Other names

Galectin-1 mRNAGal-1 mRNALGALS1 transcript14 kDa lectin mRNALectin, galactoside-binding, soluble, 1 messenger RNA

RNA interference (RNAi) or antisense-mediated degradation of mRNA to prevent translation of Galectin-1 protein.